Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.94 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.94 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.94 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.94 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.94 |
| ▸ | SRC | P12931 | 2/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.94 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.88 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.88 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.88 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.88 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.88 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.83 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.83 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.83 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.83 |
| ▸ | LDHA | P00338 | 1/20 | 0.83 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9171542 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL8979 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL12789528 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL6242713 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL18784961 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL13722152 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL13722139 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL2227081 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL20550531 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 | |
| Adenosine Triphosphate SCHEMBL8980 | 1.00 | P2RY1 (0.94) | P2RY1P2RX1P2RX3P2RY2P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113624862-B | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2023-04-07 | — | — | CN | claimed |
| CN-113624862-A | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2021-11-09 | — | — | CN | claimed |
| US-8796003-B1 | Label free kinase assays and reagents | PLEXERA, LLC (US) | 2014-08-05 | — | — | US | claimed |
| US-20120157328-A1 | Label Free Kinase Assays and Reagents | SUZHOU PUXIN LIFE SCIENCE & TECHNOLOGY., LTD. (CN) | 2012-06-21 | — | — | US | claimed |
| EP-1451211-A2 | COMPOSITIONS AND METHODS FOR MODULATING GUANYLYL CYCLASE SIGNALING RECEPTOR (GC-C) ACTIVITY AND FOR TREATING MENIERE'S DISEASE | University of Copenhagen (DK) | 2004-09-01 | — | — | EP | claimed |
| US-20040152868-A1 | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease | UNIVERSITY OF COPENHAGEN (DK) | 2004-08-05 | — | — | US | claimed |
| WO-2002079235-A2 | COMPOSITIONS AND METHODS FOR MODULATING GUANYLYL CYCLASE SIGNALING RECEPTOR (GC-C) ACTIVITY AND FOR TREATING MENIERE'S DISEASE | UNIVERSITY OF COPENHAGEN (US) | 2002-10-10 | — | — | WO | claimed |
| EP-1005327-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 2000-06-07 | — | — | EP | claimed |
| US-6063400-A | CARRIER; DIAGNOSTIC OR THERAPEUTIC AGENT AND SEQUESTERING AGENT | SDG, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-1999001110-A1 | TARGETED LIPOSOMAL CONSTRUCTS FOR DIAGNOSTIC AND THERAPEUTIC USES | SDG, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| JP-59091894-A | — | — | None | — | — | JP | disclosed |
| EP-4077344-B1 | METHODS OF SEQUENCING BY SYNTHESIS USING A CONSECUTIVE LABELING SCHEME | HOFFMANN LA ROCHE (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-118834845-A | Application of BTR1 protein in improving plant disease resistance or cultivating transgenic plant with disease resistance | 华中农业大学 | 2024-10-25 | — | — | CN | disclosed |
| US-20240300968-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | UNIV MANCHESTER (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240209408-A1 | ENGINEERED 3-O-KINASE VARIANTS AND METHODS OF USE | CODEXIS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| JP-S5991894-A | PRODUCTION OF ADENOSINE-5'-TRIPHOSPHATE | DAI ICHI SEIYAKU CO LTD | 1984-05-26 | — | — | JP | disclosed |
| US-4152209-A | CULTIVATING A STRAIN OF STREPTOMYCES OR STREPTOVERTICILLIUM | SANRAKU-OCEAN CO., LTD. (JP) | 1979-05-01 | — | — | US | disclosed |
| US-4141972-A | Purine nucleoside 5'-phosphate (mono, di or tri) 3'(2')-diphosphates and processes for their preparation | SANRAKU-OCEAN CO., LTD. (JP) | 1979-02-27 | — | — | US | disclosed |
| US-4059487-A | Purine nucleoside 5'-phosphate (mono, di or tri) 3'(2')-diphosphates and processes for their preparation | SANRAKU-OCEAN CO., LTD. (JA) | 1977-11-22 | — | — | US | disclosed |
| JP-S05991894-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300968-A1 | 6-SUBSTITUTED NAPHTHALENE-1,3-DISULFONIC ACID DERIVATIVES AS MODULATORS OF THE EXTRACELLULAR NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE (ENAMPT) FOR THE TREATMENT OF E.G. DIABETES | NAPRT, NAMPT, NUDT1 | P2RY1 87/4885P2RX1 449/4885P2RX3 783/4885 |
| US-20040152868-A1 | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease | PDE7A, PDE6C, PDE9A | P2RY1 492/4885P2RX1 730/4885P2RX3 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.